

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/395, 38/17	A1	(11) International Publication Number: WO 96/37225 (43) International Publication Date: 28 November 1996 (28.11.96)
(21) International Application Number: PCT/US96/07597 (22) International Filing Date: 24 May 1996 (24.05.96) (30) Priority Data: 450,188 25 May 1995 (25.05.95) US 60/011,867 15 February 1996 (15.02.96) US (71) Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATION [US/US]; 825 N.E. Thirteenth Street, Oklahoma City, OK 73104 (US). (72) Inventors: REICHLIN, Morris; 5801 North Stonewall Drive, Oklahoma City, OK 73162 (US). TSUZAKA, Kensei; 2-11-11-303, Sakura-Shimmachi, Setagaya-ku, Tokyo 154 (JP). ZHANG, Wei; Apartment #205, 116 N.W. Fifteenth Street, Oklahoma City, OK 73103 (US). (74) Agent: PABST, Patrea, L.; Arnall Golden & Gregory, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3450 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHOD FOR TREATMENT OF SLE (57) Abstract Treatments have been developed for lupus patients using either anti-Id antibodies to dsDNA to block anti-dsDNA antibodies and/or kill the B cells producing the anti-dsDNA antibodies or ribosomal protein S1 peptides immunoreactive with anti-dsDNA antibodies. Examples demonstrate that (1) anti-dsDNA antibodies are cross-reactive with ribosomal protein S1, (2) anti-dsDNA antibodies suppress protein synthesis, presumably through inhibition of mRNA translation initiation, and (3) a normal human sera contains an anti-idiotypic antibody (anti-Id) to anti-dsDNA antibodies isolated from SLE patients which blocked the interactions between the anti-Id antibody fragment (Fab ₂) and various anti-dsDNA preparations.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic			SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

METHOD FOR TREATMENT OF SLE

Background of the Invention

The present invention includes methods and reagents for treatment of Systemic Lupus Erythematosus ("SLE") patients characterized double stranded (ds) DNA by administration of reagents reactive with doublestranded DNA antibodies to alleviate damage resulting from the antibodies.

The U.S. government has rights in this invention by virtue of National Institutes of Health grant No. AR31133, R01 AR32214, and P01 AI2156 to Morris Reichlin.

Relationship of antibodies to dsDNA, the RNAProteins Ro/SSA, La/SSB, U₁RNP, and Sm, and clinical disease expression.

The laboratory directed by Morris Reichlin at the Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, has been engaged in the study of autoimmune responses to RNAProtein antigens in SLE patients for over 20 years. Researchers have reported the initial descriptions of the Ro/SSA (Clark, G.M., Reichlin, M. and Tomasi, T.B. *J. Immunol.*, 102:117-122 (1969)), La/SSB (Mattioli, M. and Reichlin, M. *Arthritis Rheum.*, 17:421-429 (1974)), and nRNP(U₁RNP) (Mattioli, M. and Reichlin, M. *J. Immunol.*, 107:1281-1290 (1971)) systems, while others described the Sm antigen (Tan, E.M. and Kunkel, H.G. *J. Immunol.*, 99:464-471 (1966)).

Over time, it has become apparent that certain profiles of anti-RNA protein antibodies are positively correlated with nephritis while other profiles are "negatively" correlated or "protected" from the development of serious renal disease. Thus, antibodies to nRNP(U₁RNP) alone were found to

have a low frequency of nephritis (Sharp, G.C., et al. *Am. J. Med.*, 52:148-159 (1972); Reichlin, M. and Mattioli, M. *N. Engl. J. Med.*, 286:908-911 (1972)) while patients with both anti-nRNP and anti-Sm (or anti-Sm alone) had a high frequency of nephritis (Reichlin, M. and Mattioli, M. *N. Engl. J. Med.*, 286:908-911 (1972); Maddison, P.J., et al. *J. Rheumatol.*, 5:407-411 (1978)). In patients with anti-Ro/SSA alone, a high frequency of nephritis was noted (Wasicek, C.A. and Reichlin, M. *J. Clin. Invest.*, 69:835-843 (1982); Hamilton, R.G., et al., *Arthritis Rheum.*, 31:496-505 (1988); Harley, J.B., et al. *Arthritis Rheum.*, 32(7):826-836 (1989)), while in those with both anti-Ro/SSA and anti-La/SSB, a low prevalence of nephritis was found. Studies of acid eluates from lupus nephritis kidneys have demonstrated enrichment of anti-Ro/SSA compared to serum levels (Maddison, P.J. and Reichlin, M. *Arthritis Rheum.*, 22:858-863 (1979)), supporting the participation of Ro/SSA-anti-Ro/SSA complexes in the development and/or the perpetuation of the nephritis. Elution studies of antibodies to the U₁RNP/Sm complex also showed enrichment, but the precise specificities of these complexes (anti-Sm or anti-nRNP) were not determined because of technical limitations (Koffler, et al. *J. Exp. Med.*, 134:294-312 (1971)). Serum levels of anti-Sm antibodies have been shown to fluctuate with disease activity (including nephritis) in some SLE patients (Barada, et al., *Arthritis Rheum.*, 24:1236-1244 (1981)). These data indicate a role for the Ro/SSA and Sm systems in the development of nephritis, but only 50% of patients with either anti-Ro/SSA alone or anti-nRNP and anti-Sm (or anti-Sm alone) develop nephritis.

Much data support a major role for the DNA-anti-DNA system in the pathogenesis of lupus

nephritis. Clinical studies show that high serum anti-DNA levels correlate positively with the activity of nephritis, and that remissions are associated with declining anti-DNA levels (Harley, et al., *Arthritis Rheum.* (1989); Tan, et al. *J. Clin. Invest.*, 45:1732-1740 (1966); Schur, P.H. and Sandson, J. N. *Engl. J. Med.*, 278:533-538 (1982)). Anti-DNA has been shown to be enriched in serum cryoglobulins (Winfield, et al., *J. Clin. Invest.*, 56:563-570 (1975)) and in acid eluates of lupus nephritis kidneys (Maddison and Reichlin (1979); Minitzer, et al., *Arthritis Rheum.*, 22:959-968 (1979); Beaulieu, et al. *Arthritis Rheum.*, 22:565-570 (1979)). In all these studies, the specificity of these antibodies are to dsDNA (double stranded or native DNA).

Antibodies to native or ds DNA play a special role in the clinical diagnosis and pathology of Systemic Lupus Erythematosus (SLE). These autoantibodies are highly specific, frequently correlate positively with disease activity (especially nephritis), and remissions are usually associated with declining anti-dsDNA levels (Hahn and Tsao, *Antibodies to DNA*. -Tn Dubois, Systemic Lupus Erythematosus. D- J. Wallace and B. H. Hahn, editors. (Lea and Febiger, Philadelphia, PA 1993) pp. 195-201; Harley, et al., *Arthritis Rheum.* 32:826-836 (1989); Tan, et al., *J. Clin. Invest.* 45:1732-1740 (1966); Schur and Sandson, N. *Engl. T. Med.* 278:533-538 (1982)). Patients who produce antibodies to the Ro/SSA and La/SSB (Harley, et al. (1989); Wasicek and Reichlin, *J. Clin. Invest.* 69:835-843 (1982); Hamilton, et al., *Arthritis Rheum.* 31:496-505 (1988); antigens as well as those that only have precipitins to U₁RNP (Sharp, *Am. J. Med.* 52:148-159 (1972); Reichlin and Mattioli, *N. Engl. J. Med.* 86:908-911 (1972)) very

infrequently have anti-dsDNA in their serum and have a correspondingly low prevalence of nephritis. The mechanisms of these negative relationships of antibodies to Ro/SSA and La/SSB and U₁RNP with anti-dsDNA are not understood.

Studies have been reported in the literature describing differences in the ability of murine monoclonal antibodies to dsDNA to induce nephritis when hybridomas producing these antibodies are placed in normal mice (Tsao, et al. *J. Clin. Invest.*, 85:530-540 (1990)). Others have shown that murine monoclonal antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo (Vlahakos, et al., *J. Am. Soc. Nephrol.* 2:1345-1354 (1992)). Most recently, others have reported direct in vitro binding of murine monoclonal antibodies to glomeruli which is DNA dependent (DiValerio, et al., *Clin. Res.*, 42:139A (1994)).

Reichlin, et al., *The Immunologist* 3/3, 84-88 (1995), characterizes anti-dsDNA antibodies as cross-reactive with unfolded or denatured A and D SnRNP polypeptides. Koren, et al., *J. Immunol.* 154:4857-4864 (1995), reported that murine and human antibodies to native DNA that cross-react with the A and D SnRNP polypeptides cause direct injury of cultured kidney cells. However, many questions remain about the mechanisms of lupus nephritis and the role of antibodies to dsDNA.

It is therefore an object of the present invention to provide methods and reagents for neutralizing the pathogenicity of antibodies to double stranded (ds) DNA.

It is another object of the present invention to develop specific therapy based on anti-idiotypes to anti-dsDNA.

Summary of the Invention

Treatments have been developed for lupus patients using either anti-ID antibodies to dsDNA to block anti-dsDNA antibodies and/or kill the B cells producing the anti-dsDNA antibodies or ribosomal protein S1 peptides immunoreactive with anti-dsDNA antibodies. Examples demonstrate that (1) anti-dsDNA antibodies are cross-reactive with ribosomal protein S1, (2) anti-dsDNA antibodies suppress protein synthesis, presumably through inhibition of mRNA translation initiation, and (3) a normal human sera contains an anti-idiotypic antibody (anti-Id) to anti-dsDNA antibodies isolated from SLE patients which blocked the interactions between the anti-Id antibody fragment (Fab₂) and various anti-dsDNA preparations.

Brief Description of the Drawings

Figure 1 is a graph of the inhibition of antibody binding to the recombinant protein (G7-RP) by DNA in ELISA. 5.0 µg/ml of G7-RP was used to coat the ELISA plates. 33.C9 (●), 33.H11(O), patient sera LG (▲) and JP (Δ), anti-dsDNA(AP) (■), and anti-dsDNA(IK) (□) were preincubated with 0, 0.1, 1.0, 10, 100, or 1,000 µg/ml of calf thymus dsDNA (-----) or Yeast tRNA (- - -) before being added to the plates.

Figures 2a and 2b are the nucleotide and deduced amino acid sequences of the cDNA insert in G7. Asterisks show the stop codon. This sequence has been added to the GenBank nucleic acid sequence database, Los Alamos National Laboratory, NM, and has been assigned accession number U27517.

Figures 3a and 3b are an alignment of the central core regions of 5 ribosomal proteins (r-proteins)

S1. Asterisks show the 5 repeating regions (a, b, c, d, and e, respectively). Spaces indicate positions where gaps were introduced to optimize alignment of the sequences. Dashes indicate identity to the residues of HS1. Alignment of the central core region of HS1 is residues 63-317. HS1; human r-protein S1 presented in this study, ES1; E. coli r-protein S1 (Ref. 26), RS1; Rhizobium melilotii r-protein S1 (Ref. 28), PS1, Providencia sp. r-protein S1 (Ref. 27), CS1; chloroplast r-protein S1 (Ref. 29).

Figures 4A-D are graphs comparing the affinity of 33.H11 and 33.C9 for G7-RP or DNA in inhibition ELISA. 33.H11 [A (0.0031 $\mu\text{g/ml}$) and C (1.0 $\mu\text{g/ml}$)] and 33.C9 [B (0.32 $\mu\text{g/ml}$) and D (0.56 $\mu\text{g/ml}$)] were preincubated with different concentrations of calf thymus dsDNA (●), G7-RP (○), Yeast tRNA (▲), or BSA (△), before adding the antibodies to the plates coated with calf thymus dsDNA (A and B) or G7-RP (C and D).

Detailed Description of the Invention

Therapeutic Applicants and Pharmaceutical Compositions

Based on the results in the examples, one can prepare anti-Id reagents (for anti-dsDNA) that can be used to downregulate the production of anti-dsDNA.

In one embodiment, reagents that are anti-idiotypic antibodies to anti-dsDNA could be used to down regulate or even curtail anti-dsDNA production by SLE patients.

In a second embodiment, free peptide or a conjugate of this peptide based on peptide sequence of human ribosomal protein S1 can be used in tolerance induction which could ablate anti-dsDNA.

Peptide or Protein-based Compositions.

Attempts to influence anti-DNA production in mouse lupus *in vivo* or in human lymphocytes *in vitro*, are described by Borel, et al., *Science*, 182:76-77 (1973); Borel, et al., *J. Clin. Invest.*, 61:276-286 (1978); Borel, Y. and Borel, H., *J. Clin. Invest.*, 82:1901-1907 (1988). As described by Borel, et al., oligonucleotides or nucleosides are attached to isologous (same species) IgG and this is allegedly effective in (1) inhibiting the development of an immune response to DNA in murine lupus and decreasing disease severity, and (2) inhibiting human cells from producing anti-DNA *in vitro*. The "DNA" used by Borel is single stranded or denatured which is not optimal since the most important response in SLE is to native or double stranded DNA. Borel's work provides an appropriate "carrier" for the toleragen, isologous gamma globulin.

As described herein, peptide(s) that are immunoreactive with dsDNA and are derived from the human ribosomal protein S1 can be used to induce tolerance in a patient. Antibodies to dsDNA are the disease specific pathogenic autoantibodies of the greatest interest. There are two major possibilities: (1) inject free peptide, or (2) inject peptide-coupled to human IgG, for example, coupled using glutaraldehyde or carbodiimide. These two approaches should both induce T cell tolerance. They may also be effective in inducing B cell tolerance. Both approaches are attractive since there is little chance of "boosting" the anti-dsDNA response. Should the latter occur, it can be treated by standard immunosuppressive drugs, alone or in combination with anti-La/SSB or anti-U₁RNP, as described below.

Behavior of the peptide or peptide conjugate is first studied in an appropriate animal model in order to determine efficacy and optimal dosages. There are several that could be used, but the most attractive is the Palmerston North Mouse. It has been shown that these mice, which all produce anti-dsDNA and develop nephritis, also develop anti-U₁RNP and Sm responses in almost all the animals with a dominant immune response against the A protein of U₁RNP measured in Western blot, as reported by Handwerger, et al., *Clin. Res.* 42:315A (1994). These mice have no detectable antibodies in the first three months of life but rapidly develop them after six months of age and experience a fulminant glomerulonephritis associated with anti-dsDNA antibodies. Dosage would range from 3 to 300 micrograms per mouse given weekly in the first experiments.

The same result obtained by administering peptide or a peptide conjugate can be achieved by coupling recombinant or isolated human ribosomal protein S1 to human IgG.

Although described herein with reference to the whole protein, it is preferable to use peptides of between a few amino acids up to about 100 amino acids, more preferably less than forty amino acids, still more preferably less than ten to twenty amino acids. These peptides can be easily ascertained by immobilizing the anti-dsDNA antibodies from a patient(s) and screening for binding of the peptides. Peptides can be prepared using standard techniques for amino acid synthesis or recombinantly, by engineering the cDNA encoding the protein, described in Figures 2a and 2b.

Anti-Id Antibodies That Are Immunoactive With Anti-dsDNA Antibodies.

As demonstrated by Example 3, normal human sera contains anti-Id antibodies immunoreactive

with anti-dsDNA antibodies present in many SLE patients. Antibodies for use in treating patients can be obtained using standard techniques to harvest antibodies from normal people, or, more preferably, antibody producing cells are isolated by binding of cells expressing antibody using a method as described in Example 3 for isolation of antibody. The antibody producing cells are then transformed with Epstein-Barr virus (EBV), amplified in culture, the gene encoding the variable region of the anti-Id antibodies cloned, inserted into an appropriate vector, and expressed in bacteria or another appropriate expression system, using known techniques. Preliminary studies have yielded several clones.

In either case, antibody is administered to a patient in a dosage which decreases the amount of anti-dsDNA antibody. This is readily determined since SLE patients are routinely assayed for blood levels of anti-dsDNA. In most cases patients are expected to respond as they do to standard immunosuppressive therapy, by decreasing production of anti-dsDNA antibodies. In some cases, the antibodies will result in killing of the antibody producing cells in the patient. Treatments will be repeated as required.

An alternative approach is to screen recombinant libraries of Ig variable ("V") regions made from cDNA's reverse transcribed from mRNA extracted from peripheral blood lymphocytes from patients who produce anti-anti-dsDNA antibodies. A number of such libraries can be constructed and then screened for clones reactive with Fab anti-dsDNA but not normal Fab. These can then be used to produce any desired amount of anti-idiotypic anti-dsDNA. Alternatively, murine recombinant monoclonal anti-idiotypic antibodies directed

against relevant idiotope(s) on anti-dsDNA can be produced.

This can be accomplished by the use of Pharmacia's (Pharmacia LKB Biotechnology, Sweden) "Recombinant Phage Antibody System" (RPAS), which generates a single-chain Fv fragment (ScFv) that incorporates the complete antigen-binding domain of the antibody. In the RPAS, antibody variable heavy and light chain genes are separately amplified from the hybridoma mRNA and cloned into an expression vector. The heavy and light chain domains are co-expressed on the same polypeptide chain after joining with a short linker DNA which codes for a flexible peptide. This assembly generates a single-chain Fv fragment (ScFv) which incorporates the complete antigen-binding domain of the antibody. Compared to the intact monoclonal antibody, the recombinant ScFv includes a considerably lower number of epitopes, and thereby presents a much weaker immunogenic stimulus when injected into humans. The murine ScFv molecules can be "humanized" to further reduce the immunogenic stimulus presented.

Methods for "humanizing" antibodies, or generating less immunogenic fragments of non-human antibodies, are well known. A humanized antibody is one in which only the antigen-recognized sites, or complementarily-determining hypervariable regions (CDRs) are of non-human origin, whereas all framework regions (FR) of variable domains are products of human genes.

These "humanized" antibodies present a lesser xenograft rejection stimulus when introduced to a human recipient.

To accomplish humanization of a selected mouse monoclonal antibody, the CDR grafting method described by Daugherty, et al., *Nucl. Acids Res.*,

19:2471-2476, 1991, incorporated herein by reference, can be used. Briefly, the variable region DNA of a selected animal recombinant anti-idiotypic ScFv is sequenced by the method of Clackson, T., et al., *Nature*, 352:624-688, 1991, incorporated herein by reference. Using this sequence, animal CDRs are distinguished from animal framework regions (FR) based on locations of the CDRs in known sequences of animal variable genes. Kabat, H.A., et al., *Sequences of Proteins of Immunological Interest*, 4th Ed. (U.S. Dept. health and Human Services, Bethesda, MD, 1987). Once the animal CDRs and FR are identified, the CDRs are grafted onto human heavy chain variable region framework by the use of synthetic oligonucleotides and polymerase chain reaction (PCR) recombination. Codons for the animal heavy chain CRDs, as well as the available human heavy chain variable region framework, are built in four (each 100 bases long) oligonucleotides. Using PCR, a grafted DNA sequence of 400 bases is formed that encodes for the recombinant animal CDR/human heavy chain FR protection.

The present invention will be further understood by reference to the following examples.

Example 1: Anti-dsDNA antibodies are cross-reactive with human ribosomal protein S1.

It has been reported that anti-dsDNA antibodies cross-react with a number of proteins (5-12). However, no one has reported using human anti-dsDNA antibodies as probes to clone cDNAs which encode proteins recognized by anti-dsDNA antibodies. A cDNA clone that encodes human ribosomal protein S1 which is recognized by anti-dsDNA antibodies from SLE patients has been isolated using this method.

Materials and Methods

Abbreviations: SLE, systemic lupus erythematosus; Anti-dsDNA(AP) and anti-dsDNA(IK), affinity-purified anti-dsDNA antibodies from patient sera AP and IK; GST, glutathione S-transferase; Kd, dissociation constant; TBS, tris-buffered saline; IFA, indirect immunofluorescence; G7-FP, GST-fusion protein expressed by G7; G7-RP, recombinant protein expressed by G7; r-proteins, ribosomal proteins; ES1, E.coli ribosomal protein S1; HS1, human ribosomal protein S1

Sera

Affinity-purified anti-dsDNA antibodies were eluted from DNA cellulose column (Sigma Chemical Company, St. Louis, MO) as described by Reichlin, et al., *J. Clin. Invest.* 93:443 (1994). Ten SLE patient sera containing anti-dsDNA antibodies, two samples of affinity-purified anti-dsDNA antibodies from patient sera AP and IK [anti-dsDNA(AP) and anti-dsDNA(IK), respectively], and 2 human IgG monoclonal anti-dsDNA antibodies (33.C9 and 33.H11) (Winkler, et al. *Clin. Exp. Immunol.* 85:379 (1991)) were used for characterizing cDNA clones. The isotypes and light chains of 33.C9 and 33.H11 were IgG2 (kappa) and IgG1 (lambda), respectively. Both of these monoclonal anti-dsDNA antibodies were derived from one SLE patient serum. Anti-dsDNA antibodies were detected by the Crithidia assay (Aarden, et al., *Ann. NY Acad. Sci.* 254:505 (1975)).

Screening of cDNA libraries

A phage lambda gt11 cDNA library constructed from mRNA of human liver (Clontech Laboratories Inc., Palo Alto, CA) was screened as described by Young and Davis, *Proc. Natl. Acad. Sci. USA* 80:1194 (1983) with a SLE patient (LG) serum which contained a high titer of anti-dsDNA

antibody. Serum LG also contained anti-U1RNP and anti-Ku antibodies. A positive plaque was sequentially subcloned until all progeny plaques were recognized by the serum.

5 Preparation of glutathione S-transferase
fusion protein and recombinant protein,
Western blot

EcoRI-digested cDNA insert isolated from
the recombinant phage was ligated into EcoRI-
10 digested pGEX-1 λ T expression vector (Pharmacia LKB
Biotechnology Inc., Uppsala, Sweden). The
glutathione S-transferase (GST) fusion protein was
expressed in *E. coli* and purified by using
glutathione sepharose 4B as described by Smith, et
15 al., *Gene (Amst.)* 67:31 (1988). The GST carrier
protein was removed by thrombin proteolysis to
isolate the recombinant protein.

Western blot was performed as described by Itoh, et
al., *Clin. Exp. Immunol.* 81:45 (1990). In Western
20 blot, alkaline phosphatase-conjugated goat-anti-
human IgG (Sigma Chemical Company, St. Louis, MO)
was used as the second antibody. Patient sera were
diluted to 1:100 for use in Western blot.

Treatment of sera with DNase I

25 To treat the sera with DNase I, sera were
incubated with 10 μ g/ml of DNase I (Sigma Chemical
Company, St. Louis, MO) for 1 h at 37° before
incubating with nitrocellulose (NC) membranes in
Western blot.

30 Inhibition Western blot

Inhibition Western blot reactivity of the
sera against the GST-fusion protein was
accomplished by preincubating with appropriate
dilutions of the sera for 3 h at room temperature
35 with 0, 5, 10, 50, or 100 μ g/ml of calf thymus
dsDNA or Yeast tRNA (Sigma Chemical Company, St.

Louis, MO) before incubating the sera with NC membranes bound GST-fusion protein.

Inhibition ELISA

Purified recombinant protein (5.0 µg/ml in 0.05 M carbonate bicarbonate buffer, pH 9.6) was coated on a microtiter plate well (Costar, Cambridge, MA) by incubating overnight at 4°C. For coating the plates with DNA, 0.5 mg/ml of protamine sulfate was precoated by incubating for 3 h at room temperature. After washing twice with 0.05% Tween 20 in PBS, 20 µg/ml of calf thymus dsDNA (Sigma Chemical Company, St. Louis, MO) was coated by incubating overnight at 4°C. Appropriate dilutions of the sera were preincubated with different concentrations of the recombinant protein, BSA, calf thymus dsDNA, or Yeast tRNA (Sigma Chemical Company, St. Louis, MO) for 3 h at room temperature before applying the sera to the plates. After blocking the plates with 0.1% BSA in PBS (4°C, overnight), preincubated sera were added and incubated (4°C, overnight). After washing 5 times with 0.5% Tween 20 in PBS, alkaline phosphatase-conjugated goat anti-serum IgG (Sigma Chemical Company, St. Louis, MO) was added and incubated (4°C, overnight). After washing 5 times with 0.05% Tween 20 in PBS, p-nitrophenyl phosphate substrate solution was added and the OD at 405nm as measured. % inhibition was defined as follows; % inhibition =

$$\frac{\text{OD without inhibitor} - \text{OD with inhibitor}}{\text{OD without inhibitor}} \times 100$$

Calculation of dissociation constant of antibodies

The dissociation constant (K_d)³ were calculated by Scatchard analysis as described by Friquet et al., J. Immunol. Methods. 77:305 (1985).

Preparation of MOLT4 cell extract

MOLT4 cells were collected, washed twice with 0.02M Tris-buffered saline (TBS), and were resuspended in 0.01M Tris-HCl, 0.015M NaCl, 0.0% Nonidet P-40, pH 7.2. After centrifugation at 10,00g for 15 min, the supernatant was used as MOLT4 cell extract.

Affinity purification of antibodies bound the GST-fusion protein

After the purified GST-fusion protein was electrophoresed and transferred to NC membranes, membranes were blocked with 5% skim milk solution in TBS. Membranes were then incubated with a patient serum LG for 2 h at room temperature. After washing 3 times with 0.05% Tween 20 in TBS, membrane-bound antibodies were eluted by 0.5M glycine-HCl, pH 2.9, neutralized by adding Tris base, and then concentrated using Centricon 30 concentrator (Amicon Division, W.R. Grace, Denver, MA). These purified antibodies were used as probes for Western blot using MOLT4 cell extract.

DNA sequencing

A cDNA insert isolated from a recombinant phage (EcoRI fragments) was digested with several restriction enzymes (Bgl II, EcoRV, Pst I, and Sau3A I; Promega Corp., Madison, WI) and the resulting DNA fragments were ligated into the polylinker regions of M13mp18 replicative form DNA. Nucleotide sequences were determined by using the dideoxychain termination method (Sanger, et al. *Proc. Natl. Acad. Sci. USA* 74:5463 (1977)) with T7 DNA polymerase (Dale, et al. *Plasmid* 13:31 (1985)) (U.S. Biochemical Corp., Cleveland, OH). Nucleotide and amino acid sequence were analyzed using the Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin

(Devereux, et al., *Nucleic Acids Res.* 12:387 (1984)) on a VAX 8250 computer.

Inhibition immunofluorescence

Appropriate dilutions of 33.C9 and 33.H11 were preincubated with 0, 1.0, 10, 100, or 1,000 $\mu\text{g/ml}$ of the recombinant protein, BSA, calf thymus dsDNA, or Yeast tRNA overnight at 4°C before applying the antibodies for indirect immunofluorescence (IFA)³ using Hep 2 cells. IFA using Hep 2 cells (INOVA Diagnostics, Inc., San Diego, CA) was performed as described by Gonzalez, et al., *N.Eng. J. Med.* 274:1333 (1966). FITC-labelled goat anti-human IgG (Sigma, Chemical Company, St. Louis, MO) was used at the second antibody.

Results

Isolation and characterization of a cDNA encoding a protein bound by anti-dsDNA antibody

Using a SLE patient (LG) anti-dsDNA serum as a probe, 1×10^6 clones of the human liver cDNA library in lambda gt11 phage were screened and one positive clone (termed G7) obtained. This clone was recognized by anti-dsDNA antibodies [anti-dsDNA antibody-positive patient sera LG and AC, anti-dsDNA (AP), and anti-dsDNA(1K) anti-bodies] when the β -galactosidase fusion protein was induced by isopropyl thiogalactoside. On the other hand, normal control, anti-Ku, and anti-U1RNP antibody-positive sera did not react with this fusion protein. EcoRI-digestion of the recombinant phage DNA demonstrated a 1.3-kb cDNA insert in G7.

To express the GST-fusion protein, the cDNA insert was then ligated into pGEX-1 λ T expression vector. A Western blot of the GST-fusion protein expressed by G7(G7-FP) was carried out. G7-FP (66 kDa) was electrophoresed (10% polyacrylamide gel)

and transferred to nitrocellulose membranes. NC membranes were incubated with following sera; Anti-dsDNA patient sera LG, BK, JP, WC, JH, RP, CC, JC, BJ, and AC, anti-dsDNA(AP), anti-dsDNA(IK), 33.C9, 33.H11, normal control serum, and anti-U1RNP/Sm antibody serum IA.

As shown on the Western blot, all the 10 patient sera containing anti-dsDNA antibodies (diluted to 1:100), both of the affinity-purified anti-dsDNAs (6.6 $\mu\text{g/ml}$), and both of the IgG human monoclonal anti-dsDNA antibodies (27 $\mu\text{g/ml}$ of 33.C9 and 1.8 $\mu\text{g/ml}$ of 33.H11) recognized the 66 kDa GST-fusion protein expressed by G7 (G7-FP)³ (28 kDa of 66 kDa is the GST portion and 38kDa is expected to be the recombinant part encased by G7). None of them reacted with GST carrier protein which was expressed in *E. coli* transformed with non-insert pGEX-1 λ T vector on Western blot. Inhibition of antibody binding to the GST-fusion protein or the recombinant protein by DNA was demonstrated by Western blot. G7-FP (66 kDa) was electrophoresed (10% polyacrylamide gel) and transferred to NC membranes. 33.C9 (0.27 $\mu\text{g/ml}$) was preincubated with 0, 5, 10, 50, or 100 $\mu\text{g/ml}$ of calf thymus dsDNA or Yeast tRNA before incubating with NC membranes. As demonstrated by the Western blot, 33.C9 recognized G7-FP even if 33.C9 is diluted to 0.27 $\mu\text{g/ml}$. As there is a possibility that anti-dsDNA antibodies bind to DNA in sera and this DNA which made complexes with anti-dsDNA antibodies binds to G7-FP, anti-dsDNA antibodies [33.C9 (27 $\mu\text{g/ml}$) and serum LG (diluted to 1:100)] were treated with DNase I. Treatment by DNase I did not decrease the reactivity of these antibodies against G7-FP on Western blot. This result shows that anti-dsDNA antibodies react directly with G7-FP.

To establish the specificity of antibodies which recognize the 66 kDa G7-FP in Western blot as anti-dsDNA antibodies, 33.C9 (0.27 μ g/ml) was preincubated with different concentrations of calf thymus dsDNA or Yeast tRNA before incubating with the NC membrane bound G7-FP. The reactivity of 33.C9 against G7-FP was inhibited by 5 μ g/ml of DNA but not by RNA.

G7-GP was proteolysed with thrombin to isolate the recombinant protein (G7-RP). Polyacrylamide/NaDodSO₄ gel electrophoresis (SDS-PAGE) and Western blot analysis of Gy-RP solution showed that only one recombinant protein band (42 kDa) was seen and was recognized by anti-dsDNA antibody-positive patient serum LG, anti-dsDNA (AP), anti-dsDNA (IK), 33.C9, and 33.H11 but was not recognized by normal control, anti-U1RNP, nor anti-Ku antibody-positive sera. Thus, one can conclude that this recombinant protein solution contains only G7-RP and has antigenicity.

The inhibition of antibody binding to G7-RP by DNA was also examined in ELISA (Figure 1). Two anti-dsDNA antibody-positive patient sera (LG and JP diluted to 1:10⁴), affinity-purified anti-dsDNA antibodies [anti-dsDNA(AP) and anti-dsDNA(IK), both of which were 0.33 μ g/ml, and 33.H11 (0.0071 μ g/ml) were pre-incubated with different concentrations of calf thymus dsDNA or Yeast tRNA before adding these antibodies to the plates coated with G7-RP. Reactivity of all these anti-dsDNA antibodies was inhibited almost completely (% inhibition greater than 90%) by DNA but not by RNA.

These results suggest that antibodies which recognizes G7-FP or G7-RP are anti-dsDNA antibodies.

Reactivities of the affinity-purified
antibodies eluted from G7-FP with MOLT4
cell extract.

G7-FP-transferred NC membrane was incubated
with serum LG. The antibodies that bound G7-FP
from this NC membrane were eluted. This affinity-
purified antibody at concentration of 5 μ g/ml was
positive for anti-dsDNA antibody by the Crithidia
assay and recognized G7-FP on Western blot.

The affinity-purified antibody eluted from
G7-FP was used as a probe in Western blot to
identify the responsible protein which the cDNA
insert in G7 encodes. Reactivity of the affinity-
purified antibody eluted from G7-FP with MOLT4 cell
extract was determined by SDS-PAGE (5.5%
polyacrylamide gel) transferred to NC membranes.
The NC membranes were incubated with normal control
serum, affinity-purified antibody eluted from G7-
FP, patient sera LG, AC, and JP, anti-dsDNA(AP),
anti-dsDNA(IK), 33.C9, anti-U1RNP patient serum YN,
and anti-Ku patient serum HK. A common protein
band (104 kDa) was recognized by all the anti-dsDNA
antibodies and the affinity-purified antibody
eluted from G7-FP. The affinity-purified antibody
(from serum LG) at a concentration of 5 μ g/ml
eluted from G7-FP reacted only with this 104kDa
protein.

On the other hand, normal control, anti-
U1RNP, and anti-Ku antibody-positive sera did not
react with this protein. Also in Western blot with
12.5% polyacrylamide gel using MOLT4 cell extract,
the affinity-purified antibody eluted from G7-FP
recognized only this 104kDa protein and this
protein band was commonly reactive with anti-dsDNA
antibodies (not shown). Thus, it appears that this
104 kDa protein at least in MOLT4 cell extract is

the responsible protein of which G7 encodes a portion.

Sequence analysis of the cDNA insert in G7

5 The nucleotide sequence of the cDNA insert in G7 was determined. Its primary nucleotide and deduced amino acid sequences (GenBank no. U27517) are shown in Figures 2a and 2b. The cDNA insert proved to be 1,314 nucleotides in length. The TAA stop codon is located at positions 1057-1059. The
10 predicted molecular weight for the encoded polypeptides (352 amino acids) is 38.0 kDa. However, this cDNA insert in G7 seems to be a partial length cDNA because the molecular weight of the encoded polypeptide is smaller than the
15 estimated full length size (104 kDa) of the reactive protein in MOLT4 cell extract. Thus, this cDNA does not seem to contain the initiation codon.

A search for similarities between the nucleotide sequence of the cDNA in G7 (GenBank no. U27517) and other sequences through the NCBI using
20 the BLAST network service showed a significant match (99% identity) with a sequence encoding human ribosomal protein (r-protein) S1 homologue mRNA reported by Eklund et al., Gene 155:231 (1995).
25 However, there are 3 nucleotide and 1 amino acid differences between G7 and their cDNA sequence (GTC (positions 130-132) in G7 vs GTA (positions 292-294) in their cDNA, AGT (positions 133-135, encodes Ser at residue 45) in Gy vs GCT (positions 295-297, encodes Ala at residue 99) in their cDNA].
30 Moreover, 2 nucleotides (C at positions 1355 and 1366) and 162 nucleotides (positions 1-162) in their cDNA are deleted in G7. A search was made for some similarities between the predicted amino
35 acid sequence and other protein sequences in the SWISSPROT database using the algorithm as described

by Gish, et al., *Nature Genetics* 3:266 (1993);
Altschul, et al., *J. Mol. Biol.* 215:403 (1990).

High degree of homology between the central
core region (residues 63-317) of the
5 predicted amino acid of this protein and
those of several r-proteins S1.

Identify and similarity with r-proteins S1
are the following; 39% identity and 65% similarity
with *E. coli* r-protein S1 (ES1) (26), 40% identify
10 and 64% similarity with *Providencia* sp. r-protein
s1 (Schnier, et al., *Mol. Gen. Genet.* 200:476
(1985)), 38% identity and 63% similarity with
Rhizobium meliloti r-protein S1 (Schnier, et al.,
Nucleic Acids Res. 16:3075 (1988)), and 50%
15 identity and 71% similarity with chloroplast r-
protein S1 (Franzetti, et al., *J. Biol. Chem.*
267:19075 (1992)). Moreover, 5 repeating regions
[EGTV (residue 158-161 and 243-246), DFGAFV (166-
171 and 251-256), GLVHVS (178-183 and 264-269),
20 GDKV (200-203 and 286-289), and RISLS (216-220 and
302-306)] were observed in the protein sequence.
These repeating residues have a high degree of
homology among other r-proteins S1 (Figures 3a and
3b).

Inhibition immunofluorescence

Inhibition of indirect immunofluorescence
was measured using Hep 2 cells. Staining of Hep 2
cells by 33.H11 or 33.C9 without preincubation,
after preincubation with G7-RP [100 µg/ml for
30 33.H11 or 1,000 µg/ml for 33.C9], or after
preincubation with calf thymus dsDNA [1,000 µg/ml
for 33.H11 or 1.0 µg/ml for 33.C9]. 33.H11 (0.18
µg/ml) without inhibitor added showed cytoplasmic
and nucleolar staining pattern while 33.C9 (1.7
35 µg/ml) showed homogenous nuclear staining pattern
in IFA. After preincubating with from 1.0 to 1,000
µg/ml of BSA or RNA as negative controls, these
staining patterns were not changed or diminished.

The staining pattern of 33.H11 was inhibited by 100 and 1,000 $\mu\text{g/ml}$ of G7-RP and by 1,000 $\mu\text{g/ml}$ of calf thymus dsDNA while that of 33.C9 was inhibited by from 1.0 to 1,000 $\mu\text{g/ml}$ of calf thymus dsDNA but not by any concentration of G7-RP.

Comparison of the affinity of 33.h11 and 33.C9 against G7-RP or DNA by inhibition
ELISA

The inhibition of 33.H11 and 33.C9 binding to G7-RP was compared by DNA or reciprocally binding to DNA by G7-RP in inhibition ELISA (Figures 4A-D). 33.H11 was diluted to 0.0031 $\mu\text{g/ml}$ and 1.0 $\mu\text{g/ml}$ while 33.C9 was diluted to 0.32 $\mu\text{g/ml}$ and 0.56 $\mu\text{g/ml}$ for ELISA using calf thymus dsDNA and G7-RP as antigens, respectively. These antibody concentrations were used as they gave 75% of the maximum OD for the ELISA coated with calf thymus dsDNA or G7-RP when saturating amounts of antibody were used. These antibodies were preincubated with from 0 to 1,000 $\mu\text{g/ml}$ of G7-RP, calf thymus dsDNA, bSA, or Yeast tRNA. The binding of 1.0 $\mu\text{g/ml}$ of 33.H11 to Gy-RP was not inhibited by DNA (Figure 4C) while the binding of 33.C9 was inhibited completely by DNA (Figure 4D). On the other hand, in an ELISA with DNA-coated plates, the inhibition of 33.C9 by G7-RP was far less effective (Figure 4B) compared with that of 33.H11 (Figure 4A), as about 100 times more G7-RP was required for inhibition. These data suggest that 33.H11 binds G7-RP more strongly than does 33.C9 while 33.C9 binds DNA more strongly than does 33.H11.

Kd value of 33.C9 and 33.H11 for G7-RP or DNA

From the data of the inhibition ELISA coated with G7-RP (described as the open circles in Figure 4C and 4D) and calf thymus dsDNA (described as the closed circles in Figure 4A and 4B), the Kd

value of each monoclonal anti-dsDNA antibody was calculated for G7-RP and calf thymus dsDNA as the ligands, respectively.

Before the calculation of K_d , average molecular weight of the monomeric unit of calf thymus dsDNA were determined because the size of calf thymus dsDNA is heterogeneous. If %inhibition/100 on the inhibition ELISA is defined as v , K_d (dissociation constant) can be rewritten from the Scatchard equation (Friguet, et al. 1985) as follows;

$$K_d = a_0 - i_0 v \quad (1/v - 1)$$

where a_0 and i_0 are the total concentration of the inhibitor (mol/l) and the total antibody concentration (mol/l), respectively. Therefore, if % inhibition at two different concentrations of the inhibitor added and i_0 are known, a_0 (mol/l) and molecular weight of the inhibitor can be determined even if K_d is unknown. As a result, the average molecular weight of the monomeric unit of calf thymus dsDNA was 1.0×10^6 .

K_d values of 33.c9 and 33.H11 for G7-RP or DNA were calculated by Scatchard plots. 42,000 was used as the molecular weight of G7-RP. As shown in Table I, the K_d value of 33.H11 for G7-RP was lower than that for DNA. On the other hand, K_d value of 33.C9 for DNA was two magnitudes lower than that for G7-RP. As affinities are inversely proportioned to the K_d value, these data suggest that 33.H11 has a higher affinity for G7-RP than for DNA while 33.C9 has a much higher affinity for DNA than for G7-RP. These differences of affinities correlate with the different staining patterns of IFA exhibited by the 2 monoclonal anti-dsDNA antibodies. In that view, 33.h11 binds the cytoplasm plus nucleolus where one would expect the

r-protein S1 to be localized and 33.C9 binds the nucleus where DNA is localized.

Table I. Kd (dissociation constant) (mol/l) of the two human IgG monoclonal anti-dsDNA antibodies for calf thymus dsDNA or G7-RP.

<u>antibodies</u>	<u>ligand</u>	
	<u>calf thymus dsDNA</u>	<u>G7-RP</u>
33.H11	1.0×10^{-7}	6.5×10^{-8}
33.C9	3.0×10^{-9}	3.9×10^{-7}

Discussion

In summary, a lambda gt11 cDNA library constructed from mRNA of human liver was screened by using a SLE patient serum with anti-dsDNA antibody and a clone G7 which has a 1.3-kb cDNA insert isolated. Not only all of the 10 anti-dsDNA patient sera but also affinity-purified anti-dsDNA and human IgG monoclonal anti-dsDNA antibodies recognized the protein expressed by G7. The affinity-purified antibody eluted from this protein was positive for anti-dsDNA antibody activity by the Crithidia assay. Moreover, antibody binding to this protein was inhibited completely by DNA but not by RNA. From those observations, it was concluded that anti-dsDNA antibodies cross-react with the protein expressed by G7.

A significant match (99% identify) between the nucleotide sequence of the cDNA in G& and a cDNA reported by Eklund et al. as encoding human r-protein S1 homologue mRNA. It appears that anti-dsDNA antibodies directly bind to the protein expressed by G7 because the reactivity of anti-dsDNA antibodies against the protein was not influenced by DNAase I treatment and the binding of anti-dsDNA antibodies to the protein was inhibited completely by DNA. The predicted amino acid

sequence presented in this study had homology with some r-proteins S1 including ES1. ES1 is well characterized at the functional and structural level (Subramanian, *Prog. Nucleic Acids Res. Mol. Biol.* 28:101 (1983)) while there are few reports about mammalian r-proteins S1. ES1 is the largest protein of the ribosome and has the same length as the ribosome. This protein is associated with the 30S ribosomal subunit in prokaryotes via its N-terminal globular domain and is known to stimulate translation by facilitating mRNA binding to the 30S ribosomal subunit. The central and C-terminal region contain repeating homologous sequences which are known to play a key role in the binding of structural elements of r-protein S1 to mRNA. Five repeating regions (EGTV, DFGAFV, GLVHVS, GDKV and RISLS) which repeat twice in the central core region of the protein were observed (Figures 3a and 3b). This apparent gene duplication which encodes this repeat region is absent only in the chloroplast r-protein S1.

Cytoplasmic and nucleolar staining patterns in IFA suggests that the antigenic target is the ribosome. This is the IFA pattern of human monoclonal anti-dsDNA antibody 33.H11 which is inhibited by both 100 $\mu\text{g/ml}$ of G7-RP and higher concentrations (1,000 $\mu\text{g/ml}$) of DNA. These results show that G7 encodes a ribosomal protein which is recognized by anti-dsDNA antibodies. From these observations, it is concluded that G7 encodes a part of human r-protein S1 (HS1).

It has been reported that anti-dsDNA antibodies have high frequencies of basic amino acids carrying positive charges in the heavy chain complementarity determining regions and that arginine is the most versatile amino acid for binding with negative-charged DNA (31). However,

there are no high scoring negative charged segments, which could be an epitope for anti-dsDNA antibody, in the primary sequence of HS1. These observations might suggest that cross-reactions between anti-dsDNA antibody and HS1 are not dependent on charge interaction in the primary sequence alone but rather that the cross-reactive epitope depends on conformational apposition of negative charges in the tertiary structure of HS1. However, it is likely that HS1 mimics DNA because anti-dsDNA antibodies cross-react with HS1. It is also appealing to believe that proteins which "mimic" the structure of DNA could play a role as immunogen.

Both 33.H11 and 33.C9 are IgG monoclonal anti-dsDNA antibodies (Winkler, et al., *Clin. Exp. Immunol.* 85:379 (1991)) and strongly recognized the protein expressed by G7. However, in IFA, 33.H11 did not show a homogeneous nuclear pattern and the homogeneous nuclear staining patterns of 33.C9 was not inhibited by G7-RP but was inhibited by as little as 1.0 μ g/ml of DNA. Also in ELISA, much lower concentrations of DNA were able to inhibit the binding of 33.C9 to G7-RP compared with that of 33.H11 while much higher concentrations of G7-RP were needed to inhibit the binding of 33.C9 to DNA compared with that of 33.H11. Although the binding of 33.H11 (1.0 μ g/ml) to G7-RP did not seem to be inhibited even by 1,000 g/ml of DNA (Figure 4C), that of 33.H11 (0.0071 g/ml) to G7-RP were inhibited completely by DNA (Figure 1). Therefore, it is likely that this concentration (1.0 g/ml) of 33.H11 in Figure 4C is too high to be inhibited by DNA. Analysis of K_d value showed that 33.H11 has a higher affinity for HS1 than for DNA while 33.C9 has a higher affinity for DNA than for HS1. In most anti-dsDNA-positive SLE

patient sera, anti-dsDNA antibodies behave like 33.C9 which has a higher affinity for DNA than for HS1 but indeed recognizes HS1. Anti-dsDNA antibodies of this type likely predominate because such sera rarely show a cytoplasmic and nucleolar staining pattern but rather a classical nuclear pattern but rather a classical nuclear pattern in IFA as does 33.C9.

Yanase, et al. *Lab. Invest.* 71:52 (1994), have reported that anti-dsDNA antibodies penetrate living cell membranes and bind to cytoplasmic proteins before binding to the nucleus. From these standpoint, anti-dsDNA antibodies like 33.H11 recognize HS1 strongly and are trapped in the cytoplasm preventing their entry into the nucleus. In studies with living PK15 cells, 33.H11 penetrates the plasma membrane and indeed localizes in the cytoplasm.

IT is assumed that most of the amino acid sequences which G7 encodes are mRNA-binding sites on HS1 because five repeating regions (residues 158-306) which repeat twice in HS1 and are supposed to be a feature of the mRNA binding site are observed. Therefore, if anti-dsDNA antibodies like 33.H11 bind to mRNA-binding portions on HS1, these anti-dsDNA antibodies might block the binding of mRNA to 40S (eukaryotes) ribosomal subunit, that is, the initiation reaction of translation.

Example 2: Suppression of Protein Synthesis by anti-dsDNA antibodies cross-reactive with Ribosomal Protein S1.

Four systemic lupus erythematosus (SLE) patient sera containing anti-dsDNA Antibodies, 3 affinity-purified anti-dsDNA IgG, and a human monoclonal anti-dsDNA Ab (33.H11) immunoprecipitate 18S ribosomal RNA from DNase-treated ³²P-labeled MOLT4 cell extract. This 18S RNA precipitation was

inhibited completely by preincubating 33.H11 with calf thymus dsDNA or the recombinant human ribosomal protein S1, which was described in Example 1 as cross-reactive with anti-dsDNA antibodies. 33.H11 did not immunoprecipitate 18S RNA when deproteinized labeled cell extract was used as the antigen. Whole IgG from 3 SLE sera with anti-dsDNA Antibodies, 33.H11, and 3 affinity-purified anti-dsDNA IgG inhibited *in vitro* translation of globin mRNA (% inhibition was 36-50%). This translation inhibition by anti-dsDNA Antibodies was enhanced (67-79%) when the reticulocyte lysate was treated with DNase. Suppression of protein synthesis is thereby indicated as a pathogenic mechanism of anti-dsDNA Antibodies. The r-protein S1 in *E. coli* is well known to be associated with the 30S ribosomal subunit via its N-terminal globular domain. This protein has mRNA-binding sites and plays a key role in transaction initiation by binding to mRNA in *E. coli*. In this study, anti-dsDNA Antibodies were shown to immunoprecipitate 18S ribosomal RNA and suppress *in vitro* translation of mRNA. These data are the first to demonstrate inhibition of *in vitro* protein synthesis by anti-dsDNA Antibodies.

Materials and Methods

Recombinant r-protein S1

Recombinant r-protein S1 (42 kDa) expressed from G7 clone (G&-RP) was prepared as described in Example 1.

RNA immunoprecipitation (RNA-IP)

A procedure based on that of Matter, et al. *Arthritis Rheum.* 25:1278 (1982) was used. MOLT4 cells (2×10^6 cells) were labeled with 100 μ Ci of 32 P-phosphate (ICN Pharmaceuticals Inc., Costa Mesa, CA) in RPMI 1640 medium (phosphate-free) for 16 h. Cells were washed with Tris-buffered saline (TBS),

lysed in 0.01 M tris-HCl, pH 7.2, 0.145 M NaCl, 0.5% Nonidet P-40 (NP-40) for 20 min, and centrifuged at 10,000 g for 10 min. After centrifugation, 100 μ l of the supernatant was incubated with 10 units of RQ1 DNase (RNase-free) (Promega Corp., Madison, WI) for 30 min at 37°C and was used as the labeled cell extract. Two mg of Protein A Sepharose 4B (Pharmacia LKB Biotechnology Inc., Uppsala, Sweden) preswollen in 500 μ l of NET-2 (0.01 M tris, 0.15 M NaCl, pH 7.5, 0.05% NP-40) was incubated with an appropriate amount of antibodies (10 μ l for a serum) for 15 h at 4°C, and then washed 5 times with NET-2. The antibody-bound beads were incubated for 2 h at 4°C with the labeled cell extract. After 5 washes with NET-2, the beads were incubated with 1 unit of RQ1 DNase for 30 min at 37°C. Precipitated RNAs were extracted by phenol extraction and ethanol precipitation and analyzed on polyacrylamide non-denaturing gel electrophoresis (2.5% acrylamide, 0.04 M Tris-acetate, pH 7.8, 0.02 M NaOAc, 0.002 M EDTA) (Loening, *Biochem. J.* 102:251 (1967)) followed by autoradiography.

In experiments designed to test whether proteins are necessary for antibodies to precipitate RNAs, labeled cell extract was deproteinized by phenol extraction and ethanol precipitation and then resuspended in 100 μ l of NET-2 before RNA-IP was performed as described above.

Inhibition of immunoprecipitating ability of 33.H11 by dsDNA or G7-RP

A quantity (0.1 μ g) of the human IgG monoclonal anti-dsDNA Ab 33.H11 (Winker, et al. 1991) was preincubated in 500 μ l of NET-2 with 100 μ g/ml of calf thymus dsDNA (or Yeast tRNA as a negative control) or 100 μ g/ml of G7-RP (or BSA as

a negative control) before RNA-IP was performed as described above. For RNA-IP by 33.H11 which was preincubated with calf thymus dsDNA or Yeast tRNA, labeled cell extract and washed beads were not
5 treated with RQ1 DNase.

Anti-dsDNA sera and purification of IgG

Anti-dsDNA antibodies were detected by the Crithidia assay or ELISA. For the affinity-purification of anti-dsDNA IgG, SLE patient sera
10 containing anti-dsDNA antibodies were applied to DNA cellulose columns (Sigma Chemical Company, St. Louis, MO) as described above and the eluate was incubated with 10 mg of Protein A Sepharose 4B in TBS for 15 h at 4°C. After washing 5 times with
15 TBS, IgG was eluted from the Ab-bound beads with 0.2 M glycine-HCl, pH 3.0 and concentrated after neutralization.

For purifying whole IgG from patient sera or for 33.H11 IgG, 50 µl of patient sera or 1 ml of the supernatant from the hybridoma cell culture for
20 33.H11 were incubated with 10 mg of Protein A Sepharose 4B and IgG was eluted as described above. Five SLE patient sera containing anti-dsDNA antibodies which are positive with the Crithidia assay [LG(anti-UlRNP +), AP(anti-UlRNP +), CC
25 (anti-Ro/SSA +), IK(anti-UlRNP +), JP(anti-dsDNA alone)], three samples of affinity-purified anti-dsDNA IgG from patient sera LG, Ap, and CC [anti-dsDNA(LG), anti-dsDNA(AP), and anti-dsDNA(CC),
30 respectively], and 33.H11 IgG were used as anti-dsDNA-positive samples. As negative controls, two normal human sera (DB and CW), SLE patient FF serum containing only antibodies to UlRNP and Sm (anti-UlRNP/Sm), and SLE patient NK serum containing only
35 antibodies to Ro/SSA and La/SSB (anti-Ro/La) were used. Three SLE patient sera (JC, AR, and MH) were used as anti-ribosomal protein P antibodies (anti-

P) positive sera. Antibodies to U1RNP, Sm, Ro/SSA, La/SSB, or ribosomal protein P were detected by double immunodiffusion using bovine spleen or calf thymus extract (Clark, et al., *J. Immunol.* 102:117 (1969); Mattioli and Reichlin, *Arthritis Rheum.* 17:421 (1974)). Human Cohn fraction II (Sigma) was used for normal human IgG.

Inhibition of *in vitro* translation

A procedure based on Targoff, et al., *J. Clin. Invest.* 84:162 (1989), was used, modified as follows. A standard translation reaction using a rabbit reticulocyte lysate system kit (Boehringer Mannheim Corp., Indianapolis, IN) with rabbit globin mRNA was set up, with [³H]leucine (ICN) as the labeled amino acid. Then μ l of the rabbit reticulocyte lysate was preincubated with 1 unit of RQ1 DNase (RNase-free) (Promega) (or water alone as negative control) for 30 min at 37°C. Purified IgG was dialyzed against water and concentrated. Lysate with or without DNase treatment was preincubated with IgG solution (or water alone as negative control) which contains 1 unit of RNase inhibitor (Sigma) for 2 h at 4°C. After adding all the reaction components and 5 μ l of rabbit globin mRNA (Life Technologies Inc., Gaithersburg, MD), the lysate was incubated for 1 h at 30°C to start translation (completing a 32.5- μ l reaction volume). After incubating with 3.25 μ l of 1 mg/ml RNase A for 15 min at 30°C, 5 μ l of the reaction was spotted on glass fiber filters. After washes with 5% TCA and ethanol, cpm of the filters were determined by liquid scintillation counting. Translation reaction was determined as the average of duplicate translation runs (cpm). Fidelity of the replicates was assessed by calculating the Pearson correlation coefficient. Percent inhibition was defined as follows:

$$\frac{\% \text{ inhibition}}{100} = \frac{\text{cpm after no IgG added} - \text{cpm after IgG added}}{\text{cpm after no IgG added}}$$

Results

RNA immunoprecipitation by anti-dsDNA antibodies

The labeled cell extract was treated with DNase before RNA-IP was performed because it is possible that labeled DNAs, which are precipitated by anti-dsDNA antibodies, are detected on the non-denaturing polyacrylamide gel as background. DNase-treated ³²P-labeled MOLT4 cell extract was incubated with Protein A Sepharose 4B-bound antibodies. Precipitated RNAs were analyzed on a 2.5% polyacrylamide non-denaturing gel: 33.H11 IgG (1.0 µg); anti-dsDNA-positive patient sera LG, CC, JP, IL, respectively; normal human serum DB; normal human IgG from Con fraction II (1.0 µg); affinity-purified anti-dsDNA IgG (1.0 µg each) from sera LG, AP, CC, respectively; serum NK containing only anti-Ro/La antibodies; serum FF containing only anti-U1RNP/Sm antibodies; JC and MH sera containing both anti-P and anti-dsDNA antibodies, respectively; serum AR containing only anti-P antibodies. 33.H11 (0.1 µg) was preincubated with 100 µg/ml each of Yeast tRNA, calf thymus dsDNA, BSA, or the recombinant ribosomal protein S1 (G7-RP). 33.H11 (0.1 µg) did not immunoprecipitate 18S RNA when deproteinized MOLT4 cell extract was used as the antigen. As shown in the Western blot, all four sera containing anti-dsDNA antibodies precipitated 18S RNA whereas normal human serum, serum containing only anti-Ro/La, or only anti-U1RNP/Sm antibodies did not. Moreover, 1.0 µg of 33.H11 and 1.0 µg each of affinity-purified anti-dsDNA IgG precipitated 18S RNA while 1.0 µg of normal IgG from Cohn fraction II did not. Two sera

containing both anti-P and anti-dsDNA antibodies precipitated 18S RNA whereas the serum containing only anti-P antibodies did not. Therefore, it was concluded that anti-dsDNA antibodies immunoprecipitate 18S ribosomal RNA specifically.

From the observation of RNA-IP using deproteinized MOLT4 cell extract as the source of antigen, the absence of 18S RNA precipitates by 0.1 μ g of 33.H11 IgG indicates that proteins are essential for 18S RNA immunoprecipitation by anti-dsDNA antibodies. 1.0 μ g of 33.H11 IgG did not precipitate 18S RNA, either, when deproteinized cell extract was used as the antigen.

A quantity (0.1 μ g) of 33.H11, that reacts strongly with both G7-RP and calf thymus dsDNA, was preincubated with 100 μ g/ml each of G7-RP, BSA, calf thymus dsDNA, or Yeast tRNA before RNA-IP was performed. As a result, 18S RNA immunoprecipitation by 33.H11 was inhibited completely by 100 μ g/ml each of G7-RP and calf thymus dsDNA whereas it was not blocked by the same concentration of either BSA or tRNA. These results suggest that G7-RP is essential for 18S ribosomal RNA immunoprecipitation by anti-dsDNA antibodies.

Table II. Inhibition of in vitro translation by anti-dsDNA Abs

Samples	DNase treatment of reticulocyte lysate					Change
	CPM	(-) (%INHIB)	CPM	(+) (%INHIB)		
no added IgG [mRNA(-)]	2,243	()	892	()		
no added IgG [mRNA(+)]	60,777	()	46,966	()		
<whole serum IgG>						
LG IgG (anti-dsDNA)	9μg	48,261	(20.6)	16,233	(65.4)	+44.8
AP IgG (anti-dsDNA)	9μg	56,796	(6.6)	23,358	(50.3)	+43.7
CC IgG (anti-dsDNA)	9μg	83,765	(0)	17,399	(63.1)	+63.1
FF IgG (anti-U1RNP/Sm)	9μg	72,558	(0)	47,477	(0)	0
NK IgG (anti-Ro/La)	9μg	79,896	(0)	48,678	(0)	0
DB IgG (normal)	9μg	91,999	(0)	45,598	(2.9)	+2.9
CW IgG (normal)	9μg	83,749	(0)	44,165	(6.0)	+6.0
<affinity-purified IgG>						
anti-dsDNA(LG) IgG	1μg	37,105	(38.9)	19,680	(58.1)	+19.2
	3μg	36,768	(39.5)	15,520	(67.0)	+27.5
anti-dsDNA(AP) IgG	1μg	34,539	(43.2)	12,864	(72.6)	+29.4
	3μg	35,555	(41.5)	12,659	(73.0)	+31.5
anti-dsDNA(CC) IgG	1μg	50,590	(16.8)	14,247	(69.7)	+52.9
	3μg	38,477	(36.7)	13,946	(70.3)	+33.6
33.H11 IgG	1μg	38,021	(37.4)	11,853	(74.8)	+37.4
	3μg	30,076	(50.5)	9,503	(79.8)	+29.3
Normal human IgG (Cohn fraction II)	1μg	74,470	(0)	48,714	(0)	0
	3μg	78,178	(0)	49,692	(0)	0

Each sample was tested after adding of 1, 3, or 9 μ g of IgG. CPM, average of duplicate translation runs (cpm in a 5- μ l reaction mixture). %INHIB, %inhibition defined in the text. Change, differences in % inhibition that resulted from the incubation with DNase-treated lysate as compared to the incubation with non-DNase-treated lysate.

Inhibition of *in vitro* translation by anti-
dsDNA antibodies

As shown in Table II, *in vitro* translation of rabbit globin mRNA was not affected by the addition of 9.0 μg of whole IgG from FF (anti-U1RNP/Sm), NK (anti-Ro/La), DB (normal), CW (normal) serum, or 1.0 and 3.0 μg of normal human IgG (Cohn fraction II) when either DNase-treated or non-treated reticulocyte lysate was used. The small inhibition (2.9-6.0%) noted with these negative control antibodies in the DNase-treated reticulocyte lysate was considered to be nonspecific inhibition. Nine μg of whole IgG from anti-dsDNA-positive LG, AP, or CC serum, which inhibited the translation poorly or not at all when the lysate was not treated with DNase, inhibited translation to a considerable degree (50-65%) when the lysate was treated with DNase. However, only 1.0 μg of affinity-purified anti-dsDNA IgG [anti-dsDNA(LG) and anti-dsDNA(AP)] or the monoclonal anti-dsDNA 33.H11 IgG were required for translation inhibition (38-43%) even if the lysate was not treated with DNase. Moreover, this translation inhibition by 1.0 μg of affinity-purified and anti-dsDNA and 33.H11 IgG was uniformly and significantly enhanced when the reticulocyte lysate was treated with DNase (see Table II). As the degrees of translation inhibition by 1.0 or 3.0 μg of affinity-purified anti-dsDNA and 33.H11 IgG were very similar, the inhibitory effect of anti-dsDNA IgG was apparently maximal (67-80% when DNase-treated lysate was used) with 3.0 μg of affinity-purified anti-dsDNA IgG added. The quality of the duplicate samples was reflected by the calculated value of the Pearson correlation coefficient $r^2=0.972$ for the whole data set.

Discussion

In the study of RNA-IP, it was demonstrated that anti-dsDNA antibodies precipitated only 18S RNA whereas normal human IgG and other autoantibodies (antibodies to U1RNP, Sm, Ro/SSA, La/SSB, or ribosomal protein P) did not. Also, this 18S RNA immunoprecipitation was inhibited by preincubating 33.H11 with calf thymus dsDNA or with the recombinant r-protein S1 (G7-Rp). Thus, it was concluded that anti-dsDNA antibodies precipitate 18S ribosomal RNA specifically. Moreover, it was demonstrated that r-protein S1 is essential for 18S RNA immunoprecipitation by anti-dsDNA antibodies. These results might support the evidence that r-protein S1 is located on the 40S ribosomal subunit (in eukaryotes) where 18S ribosomal RNA is an integral component. In Example 1, it was shown that the differences of the staining pattern by anti-dsDNA antibodies in IF (classical nuclear pattern versus nucleolar and cytoplasmic pattern represented by 33.H11) are due to the differences of anti-dsDNA Ab affinity between r-protein S1 and dsDNA. In the study described above, 33.H11, which has a higher affinity for r-protein S1 than for dsDNA, penetrate the plasma membrane, localizes in the cytoplasm, and remains there even after 48 hours of observation. From these standpoints, the observation of RNA-IP in this study suggests not only that the anti-dsDNA antibodies which have higher affinity for dsDNA can recognize r-protein S1 but also the possibility that anti-dsDNA antibodies recognize r-protein S1 in the cytoplasm after penetrating cell membranes. Furthermore, as RNA-IP is one of the methods for detecting antibodies to native RNA-related proteins, the results as described above indicate that anti-dsDNA

antibodies can recognize the native form of human r-protein S1.

The r-protein S1 in *E.coli* is well known to be associated with the 30S ribosomal subunit via its N-terminal globular domain. It has been reported that the major function of r-protein S1 of *E.coli* in protein synthesis is at the mRNA binding step, as described by Subramanian, *Prog. Nucleic Acids Res. Mol. Biol.* 28:101 (1983). Thus this protein plays a key role in translation initiation of *E.coli*. The translation inhibition of globin mRNA by anti-dsDNA antibodies was then determined. There are to our knowledge no published studies describing a role for r-protein S1 or its analogue in eukaryotic cells but these experiments suggest such a role. However, some anti-dsDNA antibodies might have much higher affinity for dsDNA than for r-protein S1. Therefore, the rabbit reticulocyte lysate was treated with DNase to investigate more sensitively the translation inhibition. The conclusion from these data is that anti-dsDNA antibodies inhibit the translation of globin mRNA even when some dsDNA exist in the reticulocyte lysate and that the inhibition is greatly enhanced when free dsDNA is eliminated by DNase treatment.

It is possible that anti-dsDNA antibodies inhibit the translation of mRNA by recognizing the mRNA binding sites on the eukaryotic analogue of r-protein S1 and by inhibiting the mRNA binding to r-protein S1. Demonstration of a powerful inhibition of protein synthesis by anti-dsDNA antibodies by its interaction with the human r-protein S1 provides a mechanism for a pathogenic role of anti-dsDNA antibodies after their penetration of living cells.

Exempl 3: Demonstration of Broad Cross-reactivity of an anti-Id Reagent with Anti-dsDNA from SLE patients.

Normal human serum was used as the source of the anti-Id that was prepared by passage of normal human serum over a column made with affinity purified anti-dsDNA Fab from a single lupus patient. Elution of the anti-Id with 3 M MgCl₂ and pepsin digestion resulted in anti-Id Fab₂ which was used to coat immulon plates. Five different affinity purified polyclonal anti-dsDNA populations were then shown to bind the anti-Id Fab₂ much more strongly than to normal Cohn fraction FII Fab₂, about two-fold on average. In addition two human monoclonal IgG anti-dsDNA antibody samples bound the anti-Id Fab₂ more strongly than control CFII Fab₂. In all cases dsDNA, but not RNA, blocked the interactions between the anti-Id Fab₂ and the various anti-dsDNA preparations. Affinity purified anti-Ro/SSA, anti-La/SSB, anti-U1RNP and normal CFII IgG preparations bound anti-Id Fab₂ and control CFII Fab₂ equally. This broad and specific cross-reactivity of anti-dsDNA from different SLE patients and an anti-Id (anti-anti-Id dsDNA) from a normal person has not been previously recognized and has potential as an immunologically specific reagent to block and/or downregulate anti-dsDNA in SLE.

Modifications and variations of the present invention will be obvious to those skilled in the art and are intended to come within the scope of the appended claims.

We claim:

1. A method for treating a lupus patient characterized by the presence of anti-dsDNA comprising administering to the patient a therapeutic composition in a pharmaceutically acceptable carrier for administration to a patient selected from the group consisting of peptides having sequence identity with ribosomal protein S1 which are immunoreactive with anti-dsDNA and anti-idiotypic antibody or antibody fragments immunoreactive with anti-dsDNA antibodies.
2. The method of claim 1 wherein the peptide is between four and forty amino acids in length.
3. The method of claim 1 wherein the peptide is conjugated to a carrier molecule or is a fusion protein.
4. The method of claim 1 wherein the composition is a peptide administered to a patient in an amount effective to induce tolerance.
5. The method of claim 1 wherein the composition is anti-idiotypic antibody immunoreactive with anti-dsDNA antibody.
6. The method of claim 5 wherein the antibody is administered in a dosage effective to kill anti-dsDNA antibody producing cells.
7. The method of claim 5 wherein the antibody is administered in a dosage effective to decrease the amount of anti-dsDNA antibody levels in the patient.
8. A therapeutic composition in a pharmaceutically acceptable carrier for administration to a patient selected from the group consisting of peptides having sequence identity with ribosomal protein S1 which are immunoreactive with anti-dsDNA and anti-idiotypic antibody or antibody fragments immunoreactive with anti-dsDNA antibodies.

9. The composition of claim 8 wherein the peptide is between four and forty amino acids in length.

10. The composition of claim 8 wherein the peptide is conjugated to a carrier molecule or is a fusion protein.

11. The composition of claim 8 wherein the composition is a peptide administered to a patient in an amount effective to induce tolerance.

12. The composition of claim 8 wherein the composition is anti-idiotypic antibody immunoreactive with anti-dsDNA antibody.

13. The composition of claim 12 wherein the antibody is administered in a dosage effective to kill anti-dsDNA antibody producing cells.

14. The composition of claim 12 wherein the antibody is administered in a dosage effective to decrease the amount of anti-dsDNA antibody levels in the patient.

1/7




FIG. 1

2/7

FIG. 2

GGT GAA GAA GGA GTT GTG CCA GCA CGT GAG TAC TCA GAC GAT CGT 45
 Gly Glu Glu Gly Val Val Pro Ala Arg Glu Tyr Ser Asp Asp Arg [15]

AAC ATC AAC CTG GCA GAC GAA TTA AAA ATT GGT GAT ACC ATT GAA 90
 Asn Ile Asn Leu Ala Asp Glu Leu Lys Ile Gly Asp Thr Ile Glu [30]

GCA GTT GTC ATT TCT AAC GTA ACA AGC GAC AAG GAA GGC GTC AGT 135
 Ala Val Val Ile Ser Asn Val Thr Ser Asp Lys Glu Gly Val Ser [45]

TAC TTG TTG TCA AAG AAG CGT TTG GAT GCG CGC AAG GCA TGG GAA 180
 Tyr Leu Leu Ser Lys Lys Arg Leu Asp Ala Arg Lys Ala Trp Glu [60]

AAC TTG AGC TTT GCT GAA GGT GAC ACA GTT GAT GCC AAG GTT ATC 225
 Asn Leu Ser Phe Ala Glu Gly Asp Thr Val Asp Ala Lys Val Ile [75]

AAC GCT GTT CGT GGT GGT TTG ATT GTT GAT GTT AAC GGC GTA CGT 270
 Asn Ala Val Arg Gly Gly Leu Ile Val Asp Val Asn Gly Val Arg [90]

GGT TTC GTA CCA GCA TCA ATG GTT GCA GAA CGT TTC GTT TCT GAT 315
 Gly Phe Val Pro Ala Ser Met Val Ala Glu Arg Phe Val Ser Asp [105]

TTG AAC CAA TTC AAG AAT AAG GAT ATT AAA GCA CAA GTT ATC GAA 360
 Leu Asn Gln Phe Lys Asn Lys Asp Ile Lys Ala Gln Val Ile Glu [120]

ATT GAC CCT GCT AAT GCA CGT TTG ATT TTG TCA CGT AAG GCT GTT 405
 Ile Asp Pro Ala Asn Ala Arg Leu Ile Leu Ser Arg Lys Ala Val [135]

GCT GCA CAA GAA CGC GCT GCA CGA TTG GCT GAA GTA TTT AGC AAG 450
 Ala Ala Gln Glu Arg Ala Ala Gln Leu Ala Glu Val Phe Ser Lys [150]

TTG TCA GTT CGT GAA GTT GTT GAA GGA ACT GTT GCC CGT TTG ACA 495
 Leu Ser Val Gly Glu Val Val Glu Gly Thr Val Ala Arg Leu Thr [165]

GAC TTC GGC GCA TTC GTT GAC TTG GGT GGT GTT GAT GGT TTG GTT 540
 Asp Phe Gly Ala Phe Val Asp Leu Gly Gly Val Asp Gly Leu Val [180]

CAC GTA TCA GAA ATC TCA CAC GAT CGT GTG AAG AAC CCG GCC GAT 585
 His Val Ser Glu Ile Ser His Asp Arg Val Lys Asn Pro Ala Asp [195]

GTA TTG ACA AAG GGT GAC AAG GTT GAT GTT AAG ATC TTG GCA TTG 630
 Val Leu Thr Lys Gly Asp Lys Val Asp Val Lys Ile Leu Ala Leu [210]

GAC ACT GAA AAG GGT CGT ATC TCA TTG TCA ATC AAA GCA ACA CAA 675
 Asp Thr Glu Lys Gly Arg Ile Ser Leu Ser Ile Lys Ala Thr Gln [225]

FIG. 2a

CGT GGA CCT TGG GAC GAA GCT GCA GAT CAA ATC GCT GCA GGT TCA 720
 Arg Gly Pro Trp Asp Glu Ala Ala Asp Gln Ile Ala Ala Gly Ser [240]

GTG CTT GAA GGT ACT GTT AAG CGT GTG AAG GAC TTT GGT GCC TTT 765
 Val Leu Glu Gly Thr Val Lys Arg Val Lys Asp Phe Gly Ala Phe [255]

GTT GAA ATT TTG CCT GGT ATC GAA GGT CTT GTG CAC GTG TCA CAA 810
 Val Glu Ile Leu Pro Gly Ile Glu Gly Leu Val His Val Ser Gln [270]

ATT TCA AAC AAG CGT ATT GAA AAC CCA TCA GAA GTT TTG AAG TCT 855
 Ile Ser Asn Lys Arg Ile Glu Asn Pro Ser Glu Val Leu Lys Ser [285]

GGT GAC AAG GTA CAA GTG AAG GTA TTG GAC ATT AAG CCA GCC GAA 900
 Gly Asp Lys Val Gln Val Lys Val Leu Asp Ile Lys Pro Ala Glu [300]

GAA CGT ATT TCA TTG TCA ATG AAG GCT TTG GAA GAA AAG CCA GAA 945
 Glu Arg Ile Ser Leu Ser Met Lys Ala Leu Glu Glu Lys Pro Glu [315]

CGT GAA GAT CGT CGT GGT AAC GAT GGT TCA GCT TCA CGT GCT GAT 990
 Arg Glu Asp Arg Arg Gly Asn Asp Gly Ser Ala Ser Arg Ala Asp [330]

ATC GCT GCT TAC AAG CAA CAA GAT GAC TCA GCC GCA ACA TTG GGT 1035
 Ile Ala Ala Tyr Lys Gln Gln Asp Asp Ser Ala Ala Thr Leu Gly [345]

GAC ATC TTT GGT GAT AAG TTG TAA GAGGCATCAACATAAAAGAGCTGGTTC 1086
 Asp Ile Phe Gly Asp Lys Leu *** [352]

GCCAGTTCCTTTATTTTGAAGAAAAATTGAGTGGGCATTAGTGGGCGCTCACGGTATG 1145

AAAAAGGAGGTGCGATTATGGCAGCACCAGTAGTAGCCATTGTTGGCGACCAAACGTCTG 1204

GAAAATCGACTATCTTTAACCGGATGGCCGGAGAACGTATTGCAATTGTTGAAGATCAA 1263

CCAGGGGGTAACACGCGATCGTTTGTACGCGCCAGCCGAATGTTGAATTAT 1314

FIG. 3a

HS1	240	SVLEGT	KRVK	DFGAF	VEILP	GI	GLVH	VSVQ	ISNK	RIENP	SEVL	KSGD	KVQV	KVLD	KIP	298
ES1	278	TK-T	-R-	TNLT	-Y-C	----	EE-V	-----	EM	RD-V	DATL	--SV	--E-	EA-	FTGVDR	510
RS1	284	KKIS	---	TNIT	-Y-	-----	LE-	-----	I-I	-EM	-RPG	-QVI	-EFNK	--V-	RAV	430
PS1	173	TK-T	-R-	TNLT	-Y-C	----	EE-V	-----	EM				-K	--E	IAAV	319

e

HS1	299	AEERIS	LSMK	ALEEK	PERE	317
ES1	511	KNRA	---	VR-KD	-AD-KD	529
RS1	431	DK	----	GI-QL		442
PS1	320	ER	-----	GV-QLA	-DP	335

6/7




FIG. 4a




FIG. 4b

7/7




FIG. 4c




FIG. 4d

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/07597

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K39/395 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SPRINGER SEMINARS IN IMMUNOPATHOLOGY, vol. 7, no. 1, 1984, BERLIN, GERMANY, pages 25-34, XP000605499 B. HAHN: "Suppression of autoimmune diseases with anti-idiotypic antibodies: Murine lupus nephritis as a model." see page 32, line 14 - line 23 ---	1,5-8, 12-14
X	IMMUNOLOGY, vol. 74, no. 2, October 1991, OXFORD, GB, pages 342-347, XP000608109 C. RAVIRAJAN ET AL.: "Involvement in lupus disease of idiotypes Id.F-423 and Id.IV-228 defined, respectively, upon foetal and adult MRL/Mp-lpr/lpr DNA-binding monoclonal autoantibodies." see page 346, left-hand column, line 1 - line 6 ---	1,5-8, 12-14

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

18 October 1996

Date of mailing of the international search report

05. 11. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Nooij, F

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/07597

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 83, no. 1, January 1991, OXFORD, GB, pages 126-132, XP000608102 C. MORLAND ET AL.: "Anti-idiotypic and immunosuppressant treatment of murine lupus." see abstract ---	1,5-8, 12-14
X	THE JOURNAL OF IMMUNOLOGY, vol. 142, no. 4, 15 February 1989, BALTIMORE, MD, USA, pages 1159-1165, XP002016364 T. SASAKI ET AL.: "In vitro manipulation of human anti-DNA antibody production by anti-idiotypic antibodies conjugated with neocarzinostatin." see abstract ---	1,5-8, 12-14
A	NUCLEIC ACIDS RESEARCH, vol. 19, no. 15, 11 August 1987, OXFORD, GB, page 4297 XP002016365 D. GRABOWSKI ET AL.: "Drosophila AP3, a presumptive DNA repair protein, is homologous to human ribosomal associated protein P0." see the whole document ---	1-4,8-11
A	WO 94 21669 A (MEDCLONE, INC.) 29 September 1994 see the whole document ---	1-4,8-11
A	EP 0 113 431 A (YESHIVA UNIVERSITY) 18 July 1984 see claims ---	1,5-8, 12-14
P,X	ARTHRITIS & RHEUMATISM, vol. 38, no. 9 suppl., September 1995, NEW YORK, NY, USA, page S274 XP000608103 K. TSUZUKA ET AL.: "Lupus autoantibodies to double-stranded DNA cross-react with ribosomal protein S1." see abstract 726 ---	1-4,8-11
P,X	THE JOURNAL OF IMMUNOLOGY, vol. 156, no. 4, 15 February 1996, BALTIMORE, MD, USA, pages 1668-1675, XP002016366 K. TSUZUKA ET AL.: "Lupus autoantibodies to double-stranded DNA cross-react with ribosomal protein S1." see abstract -----	1-4,8-11

INTERNATIONAL SEARCH REPORT

In ternational application No.

PCT/US 96/ 07597

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1 - 7
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/07597

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9421669	29-09-94	NONE	
EP-A-113431	18-07-84	US-A- 4692416	08-09-87
		AU-B- 566246	15-10-87
		AU-A- 2171283	07-06-84
		CA-A- 1215009	09-12-86
		JP-A- 59122951	16-07-84
		US-A- 4690905	01-09-87